Vontobel Holding Ltd. Has $191.76 Million Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Vontobel Holding Ltd. raised its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 9.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 456,621 shares of the company's stock after purchasing an additional 38,058 shares during the period. Vontobel Holding Ltd. owned 0.56% of IDEXX Laboratories worth $191,758,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. United Capital Financial Advisors LLC lifted its stake in IDEXX Laboratories by 0.9% in the fourth quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after acquiring an additional 22 shares during the last quarter. PDS Planning Inc raised its holdings in shares of IDEXX Laboratories by 3.9% during the 1st quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after purchasing an additional 24 shares in the last quarter. Gabelli Funds LLC lifted its stake in shares of IDEXX Laboratories by 5.3% in the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after purchasing an additional 25 shares during the last quarter. Bigelow Investment Advisors LLC lifted its stake in shares of IDEXX Laboratories by 1.9% in the 1st quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock valued at $596,000 after purchasing an additional 27 shares during the last quarter. Finally, Forum Financial Management LP boosted its holdings in IDEXX Laboratories by 4.9% in the fourth quarter. Forum Financial Management LP now owns 621 shares of the company's stock worth $257,000 after purchasing an additional 29 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on IDXX shares. Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Leerink Partners raised their price objective on IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Stifel Nicolaus upped their target price on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Jefferies Financial Group initiated coverage on IDEXX Laboratories in a report on Tuesday. They set a "buy" rating and a $625.00 price target on the stock. Finally, Morgan Stanley boosted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $554.78.

IDEXX Laboratories Stock Performance

IDXX stock traded up $6.31 during trading on Tuesday, reaching $542.65. 631,445 shares of the stock were exchanged, compared to its average volume of 645,012. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $546.58. The company has a current ratio of 1.16, a quick ratio of 0.81 and a debt-to-equity ratio of 0.31. The company has a market capitalization of $43.64 billion, a P/E ratio of 50.15, a price-to-earnings-growth ratio of 3.88 and a beta of 1.55. The stock has a 50 day simple moving average of $501.61 and a 200-day simple moving average of $451.67.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million during the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 57.35% and a net margin of 22.76%. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.71 earnings per share. As a group, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the firm's stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the completion of the transaction, the director owned 1,801 shares in the company, valued at $922,724.34. This trade represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.98% of the stock is owned by company insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.